The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth

VBCC - March 2016, Vol 7, No 2 - Online First, VBCC Perspectives
Robert W. Carlson, MD
Al B. Benson III, MD, FACP

A recently published perspective in Value-Based Cancer Care1 criticized the National Comprehensive Cancer Network (NCCN) Evidence Blocks initiative. Regrettably, that perspective is extremely misleading and is full of innuendo and misuse of statistics.

In the perspective, the author stated that there is no “drug cost problem.”1 The statistics cited by the author document an $88-billion increase in cancer care costs in the United States between 1995 and today. The author’s conclusion is that “The assertion that cancer costs are unsustainable is false.”1 Most physicians and patients with cancer in the United States would be astounded by that statement.

The NCCN Evidence Blocks provide expert scoring on a 5-point scale for efficacy, safety, quality of supporting data, consistency of supporting data, and the overall cost of specific systemic cancer therapies. The NCCN Evidence Blocks do not make the value judgment or recommendation for which option is best, nor is there any recommendation for what portion of the costs should be borne by the patient, the payer, or another entity. The NCCN Evidence Blocks are decision tools that help to further inform the discussion between the patient and the clinician. As is true with the composite NCCN guidelines, the Evidence Blocks are not prescriptive but rather are a comprehensive information resource to be used in shared decision-making.

Contrary to the assertion in the perspective mentioned earlier, the NCCN makes no recommendation or assessment of “insurer-imposed out-of-pocket cost.”1 To suggest otherwise is simply not true. The NCCN is unaware of any payer who is now using or who plans to use the NCCN Evidence Blocks in making coverage determinations. Payers already know with substantial confidence and precision what the cost of a specific cancer care intervention is, and they do not need the NCCN Evidence Blocks to inform them.

At the current time, patients usually have little idea what the cost of care is before their treatment, either in total or what their share to pay will be. If cost is important to a patient, the NCCN Evidence Blocks highlight affordability so that patient-specific financial counseling can be performed. More than 60% of personal bankruptcies in the United States are healthcare bankruptcies.2 Patients and providers require information that respects the autonomy of patients and provides them with meaningful information as they make their own treatment decisions.

The statement that the NCCN Evidence Blocks will be responsible for increasing the rate of suicide among oncology patients by cost-shifting is disingenuous. The author of that perspective stated that a survey of patients who chose assisted suicide in Oregon shows that since 1998, the number of people citing the cost of care as a reason for their decision increased by 77%.1 The reality is that in 1998, there were a total of 15 physician-assisted suicides in Oregon.3 The end-of-life concerns for these 15 patients who died after lethal medication were loss of autonomy as a result of illness (80%); the inability to participate in activities (67%); the loss of control of bodily function (53%); placing a burden on family, friends, or caregivers (13%); inadequate pain control (7%); and the financial cost of treating or prolonging illness (0%).3

In 2014, the corresponding end-of-life concerns of the 105 patients who died through physician-assisted suicide in Oregon included: losing autonomy (91.4%); being less able to engage in activities making life enjoyable (86.7%); the loss of dignity (71.4%); losing control of bodily functions (49.5%); placing a burden on family, friends, or caregivers (40%); inadequate pain control or concern about it (31.4%); and financial implications of treatment (4.8%).4 Financial costs or implications were the least common cause for physician-assisted suicide in Oregon in 1998 and in 2014, with a frequency that has not changed (chi-square P value, 0.39).

The NCCN Evidence Blocks are a serious, credible attempt to provide transparency to medical decision-making for all stakeholder groups. Criticism is certainly welcome to improve the NCCN Guidelines and the NCCN Evidence Blocks. However, allegations that the NCCN Evidence Blocks initiative is supporting the shifting of costs to patients, discouraging rescue therapy, limited to single-agent therapy, and encouraging patient suicide are simply false.

The NCCN believes that healthcare providers, patients, and other stakeholders deserve to be provided with accurate, helpful information and education. The NCCN does not believe that withholding important information and knowledge about cancer care and healthcare delivery from patients is honest or productive. The NCCN believes that hope is appropriate, and we strive to advance the quality, effectiveness, and efficiency of cancer care on a continuous basis, so that patients may have hope that is honest, helpful, and productive.

View The Referenced Article


  1. Goldberg R. The NCCN new tool to assess value discourages patients’ hope. Value-Based Cancer Care. 2015;6 (9):7.
  2. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122:741-746.
  3. Chin AE, Hedberg K, Higginson GK, Fleming DW. Oregon’s Death with Dignity Act: the first year’s experience. February 18, 1999. Accessed December 10, 2015.
  4. Oregon Public Health Division. Oregon’s Death with Dignity Act—2014. Accessed December 10, 2015.
Related Items
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Drug Updates, Online First
Nursing Certification Through Portfolio Promotes Professional Development and Performance
Wayne Kuznar
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Online First, The Rheumatology Nurse
The NCCN New Tool to Assess Value Discourages Patients’ Hope
Robert Goldberg, PhD
VBCC - November 2015, Vol 6, No 10 published on November 12, 2015 in VBCC Perspectives
AstraZeneca Commentary on Oncology Value Tools
Diane Sullivan
VBCC - October 2015, Vol 6, No 9 published on October 17, 2015 in VBCC Perspectives
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework a Powerful Tool for Shared Decision-Making
Neil B. Minkoff, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Emerging Tools for Assessing Value: Pros and Cons
Kirby J. Eng, RPh
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Promoting Accountability and Transparency
Joseph Morse
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
Pamela Pelizzari, MPH, Bruce Pyenson, FSA, MAAA
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
Philip E. Johnson, MS, RPh, FASHP
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Last modified: January 9, 2020
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology